Valneva stock retreats nearly 3%, sliding to the bottom of the SBF 120
The Lyon-based laboratory is losing ground this Wednesday, amid a European market under pressure, with the SBF 120 down nearly 1.8% in trading. The decline comes after several weeks of strong monthly gains, while the stock maintains a comfortable technical advantage over its short and medium-term moving averages.
A decline of 2.9% that erases only a fraction of the 27% monthly rebound
Valneva is down 2.89% to €2.89 in trading, while the previous day the stock closed at €2.97. The decline remains modest compared to the ground covered over the past month: the stock still shows nearly 27.5% gains over thirty days, after approaching its resistance level at €3.07 in previous sessions. Over one week, performance remains positive at approximately 2.9%, illustrating the strength of the bullish momentum initiated since mid-August. With a rank of 105 out of 120 SBF 120 members, Valneva is among the most underperforming values on the index this Wednesday, in a session marked by generalized selling pressure on European equities.
The CAC 40 is down 1.86% in trading, and Sanofi, a comparable sector player, is down 1.2%. Net short positions declared by three funds stand at 2.58% of capital, down 0.72 points over thirty days (versus 3.30% a month ago), according to consulted declarations. This partial short-covering movement, conducted against the backdrop of the stock's rebound, testifies to a gradual easing of institutional downward pressure, without signaling total capitulation.
The 50-day moving average at €2.46 offers solid support, resistance at €3.07 remains the immediate target
On key technical levels, the stock remains above its 20-day moving average at €2.84 (spread of +1.65%) and well above its 50-day moving average at €2.46, with a spread of nearly 17.5%. This double cushion testifies to the strength of the rebound initiated since summer. Conversely, the 200-day moving average at €3.17 continues to weigh above the current price, with a negative spread of 8.9%, indicating that the long-term trend remains bearish. The RSI at 64 reflects a tight configuration without being overbought: the stock has room before reaching the 70 zone, but this Wednesday's decline occurs in a context of a slightly negative MACD (histogram at -0.011), signaling a loss of momentum in the very short-term upside dynamic.
The resistance at €3.07, already approached in early September, remains the threshold to overcome to confirm an upside breakout. The support at €2.15 remains well below the current price. Furthermore, upon publication of H1 2026 results on August 13, 2026, the company had confirmed its annual targets despite a net loss widened to €63.3 million in the first half, highlighting the concentration of resources on its key strategic projects, including the regulatory progress of its candidate vaccine against Lyme disease, with the dossier currently under review by the EMA.
